AU2005279308B2 - Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use - Google Patents

Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use Download PDF

Info

Publication number
AU2005279308B2
AU2005279308B2 AU2005279308A AU2005279308A AU2005279308B2 AU 2005279308 B2 AU2005279308 B2 AU 2005279308B2 AU 2005279308 A AU2005279308 A AU 2005279308A AU 2005279308 A AU2005279308 A AU 2005279308A AU 2005279308 B2 AU2005279308 B2 AU 2005279308B2
Authority
AU
Australia
Prior art keywords
hmgb1
biologically active
active fragment
box
polypeptide variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005279308A
Other languages
English (en)
Other versions
AU2005279308A1 (en
Inventor
Domenico G. Barone
Luisa Bertarione Rava Rossa
Gilles Borrelly
Barbara Canepa
Lila Drittanti
Silvano Fumero
Thierry Guyon
Chiara Lorenzetto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creabilis Therapeutics SpA
Original Assignee
Creabilis Therapeutics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creabilis Therapeutics SpA filed Critical Creabilis Therapeutics SpA
Publication of AU2005279308A1 publication Critical patent/AU2005279308A1/en
Assigned to CREABILIS THERAPEUTICS S.R.L. reassignment CREABILIS THERAPEUTICS S.R.L. Amend patent request/document other than specification (104) Assignors: CREABILIS THERAPEUTICS S.R.L.
Application granted granted Critical
Publication of AU2005279308B2 publication Critical patent/AU2005279308B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
AU2005279308A 2004-09-03 2005-09-05 Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use Ceased AU2005279308B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04425665.9 2004-09-03
EP04425665 2004-09-03
PCT/EP2005/009528 WO2006024547A2 (en) 2004-09-03 2005-09-05 Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use

Publications (2)

Publication Number Publication Date
AU2005279308A1 AU2005279308A1 (en) 2006-03-09
AU2005279308B2 true AU2005279308B2 (en) 2012-05-03

Family

ID=35768125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005279308A Ceased AU2005279308B2 (en) 2004-09-03 2005-09-05 Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use

Country Status (10)

Country Link
US (2) US7635679B2 (https=)
EP (1) EP1797118A2 (https=)
JP (1) JP5622351B2 (https=)
KR (1) KR101249287B1 (https=)
AU (1) AU2005279308B2 (https=)
BR (1) BRPI0514835A (https=)
CA (1) CA2579094C (https=)
MX (1) MX2007002557A (https=)
NZ (1) NZ553809A (https=)
WO (1) WO2006024547A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006124477A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
DE602007013919D1 (de) * 2006-09-15 2011-05-26 Creabilis Therapeutics Spa Polymerkonjugate von box-a von hmgb1 und box-a-varianten von hmgb1
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
EP2492281B1 (en) * 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
KR101279641B1 (ko) * 2011-01-05 2013-06-27 인하대학교 산학협력단 Ｈｉｈｐ－２를 유효성분으로 함유하는 신경보호용 조성물
EP2703487B1 (en) * 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
US9956195B2 (en) * 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018257071B2 (en) * 2017-04-25 2021-11-11 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) * 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2020085506A1 (ja) * 2018-10-25 2020-04-30 国立大学法人大阪大学 軟骨疾患の治療薬
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
JP7455433B2 (ja) * 2020-04-22 2024-03-26 チュラーロンコーン ユニバーシティー Ｄｎａを回復する及びｄｎａ損傷を防止する組成物及び方法
CN113151329B (zh) * 2021-03-30 2023-09-08 云南师范大学 中性蛋白酶突变体及其构造方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092004A2 (en) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Use of hmg fragment as anti-inflammatory agents
WO2004046345A2 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20060204537A1 (en) * 2002-06-21 2006-09-14 Genzyme Corporation Silicone blends and composites for drug delivery
EP1539950A1 (en) * 2002-09-09 2005-06-15 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
PL376169A1 (en) * 2002-11-15 2005-12-27 Novartis Ag Drug delivery system
JP2004222953A (ja) * 2003-01-22 2004-08-12 Kanegafuchi Chem Ind Co Ltd 生体留置用ステント
CH694905A5 (it) * 2003-03-25 2005-09-15 Marco Ostini Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092004A2 (en) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Use of hmg fragment as anti-inflammatory agents
WO2004046345A2 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FACIOLA, L. et al. Nucleic Acids Research. 1994, Vol. 22, No. 3, pages 285-292 *
FARID, R. S. et al. Toxicology and Applied Pharmacology. 1996, Vol. 141, pages 532-539 *

Also Published As

Publication number Publication date
CA2579094A1 (en) 2006-03-09
US20080038309A1 (en) 2008-02-14
KR20070059128A (ko) 2007-06-11
MX2007002557A (es) 2007-10-10
JP5622351B2 (ja) 2014-11-12
US7635679B2 (en) 2009-12-22
WO2006024547A3 (en) 2006-06-01
BRPI0514835A (pt) 2008-06-24
JP2008511300A (ja) 2008-04-17
CA2579094C (en) 2014-12-02
NZ553809A (en) 2010-03-26
EP1797118A2 (en) 2007-06-20
US8058232B2 (en) 2011-11-15
AU2005279308A1 (en) 2006-03-09
US20110052493A1 (en) 2011-03-03
KR101249287B1 (ko) 2013-04-01
WO2006024547A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
AU2005279308B2 (en) Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use
Cambier et al. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention
EP1768677B1 (en) Nucleic acids for the treatment of hmgb1-related pathologies
CA2663300C (en) Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
BRPI0718491A2 (pt) Conjugados poliméricos do box-a da hmgb1 e variantes do box-a da hmbg1
JP6566947B2 (ja) Ｍａｐキナーゼｐ３８結合化合物
JP2022536797A (ja) 炎症性状態を処置するための方法および組成物
Darlot Design of modulatory peptides against chemokines
WO2011132939A2 (ko) Rtk에 특이적으로 결합하는 rtk-bpb
HK1134779B (en) Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired